



Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Opicapone (Ongentyl®)
Indication under review	Adjunctive therapy to levodopa/DDCI preparations in adults with Parkinson Disease and end-of-dose
Policy No:	APC 149
Date of Issue:	May 2017
Review Date:	May 2018 (review after audit)
Policy Statement: Opicapone should be used only as a second line treatment for patients unable to take entacapone due to side-effects under the directions of a neurologist.	
Traffic Light Status	Amber
Key Points considered: <ul style="list-style-type: none"> • The application was presented and supported by a Consultant Neurologist. • He described the treatment of choice as being entacapone however this is a treatment that is given up to 5 times a day and for some patients, side-effects such as diarrhoea limit use of this drug. • About 8%-10% of patients will suffer intolerable side-effects and opicapone would be reserved for this small cohort of patients. • Treatment is a once daily tablet therefore reducing the pill burden. • The 2 pivotal studies (BIPARK 1 and BIPARK 2) both achieved their primary endpoint demonstrating an absolute reduction in OFF-time. • This policy will be reviewed in a years time to review the place in therapy including patient numbers and emerging evidence. 	
References Andrew J Less, Joaquim Ferreira, Olivier Rascol et al. BIPARK-2 Study Investigators Opicapone as Adjunct to Levodopa Therapy in Patients with Parkinson Disease and Motor Fluctuations. A randomized Clinical Trial JAMA Neurol.2017; 74 (2): 197-206 doi10.1001/jamaneurol. 2016.4703	
Date taken to APC:	3 rd May 2017
Date Ratified by GPMOC on Behalf of the Board:	21 st June 2017

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only